Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Pharmacologic Prevention Of Post-ERCP Pancreatitis: Is Nitroglycerin A Sangreal?

V. Muralidharan, P. Jamidar
Published 2006 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1056/NEJM199609263351302
Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group.
G. Cavallini (1996)
10.1016/S0016-5107(05)01572-5
Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis.
P. Mosler (2005)
10.1016/0016-5085(88)90182-5
Effect of nifedipine on sphincter of Oddi motor activity: studies in healthy volunteers and patients with biliary dyskinesia.
M. Guelrud (1988)
10.1136/gut.42.4.507
Effects of botulinum toxin A on the sphincter of Oddi: an in vivo and in vitro study
J. A. Sand (1998)
10.1056/NEJM199609263351302
Gabexate mesilate for the prevention of acute pancreatitis following endoscopic retrograde cholangiopancreatography.
G. Cavallini (1996)
10.1136/gut.35.9.1319
Intrasphincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction.
P. Pasricha (1994)
The secret (GTN) of successful ERCP cannulation: a prospective randomised controlled study.
A. Ghori (2002)
Mechanical prevention of post-ERCP pancreatitis by pancreatic stents: results, techniques, and indications.
P. Tarnasky (2003)
10.1016/S0016-5107(00)14046-5
3346 Evaluation of recombinant human plateletactivating factor acetylhydrolase (rpaf-ah) for reducing the incidence and severity of post-ercp acute pancreatitis (ap).
S. Sherman (2000)
10.1016/S0016-5107(95)70128-1
A comparison of nonionic versus ionic contrast media: results of a prospective, multicenter study. Midwest Pancreaticobiliary Study Group.
G. K. Johnson (1995)
10.1097/00004836-199706000-00009
Sincalide: a cholecystokinin agonist as an aid in endoscopic retrograde cholangiopancreatography--a prospective assessment.
A. Weston (1997)
10.1055/S-2001-13687
Topical application of nitrates onto the papilla of Vater: manometric and clinical results.
T. Wehrmann (2001)
10.1055/S-2007-1018393
A randomized double-blind trial of cholecystokinin during ERCP.
J. Thompson (1986)
10.1111/J.1365-2125.1992.TB04074.X
Efficacy of nifedipine therapy in patients with sphincter of Oddi dysfunction: a prospective, double-blind, randomized, placebo-controlled, cross over trial.
M. Khuroo (1992)
10.1067/MGE.2002.122616
Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP?
T. Rabenstein (2002)
10.1016/S0016-5107(91)70740-2
Endoscopic sphincterotomy complications and their management: an attempt at consensus.
P. Cotton (1991)
10.1016/S0016-5107(05)00653-X
Efficacy of Recombinant Human Interleukin-10 in Prevention of Acute Pancreatitis After ERCP in Subjects with Increased Risk: Randomized Prospective Multicenter Study
S. Sherman (2005)
10.1067/MGE.2003.307
Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study.
S. Sherman (2003)
10.1016/S0016-5107(04)00159-2
Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis.
T. Rabenstein (2004)
10.1016/S0002-9270(99)00054-4
Use of corticosteroids in the prevention of post-ERCP pancreatitis: results of a controlled prospective study
G. D. Palma (1999)
10.1055/S-2007-1001392
Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction.
T. Wehrmann (1998)
10.1016/J.GIE.2005.11.060
A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis.
A. Kaffes (2006)
10.1016/0016-5085(85)90004-6
Endoscopic removal of common bile duct stones through the intact papilla after medical sphincter dilation.
M. Staritz (1985)
10.1016/S0016-5107(94)70204-7
Post-ERCP pancreatitis: randomized, prospective study comparing a low- and high-osmolality contrast agent.
S. Sherman (1994)
10.1016/S0016-5085(03)00384-6
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
B. Murray (2003)
10.1046/j.1365-2036.2000.00814.x
Endoscopic injection of botulinum toxin in patients with recurrent acute pancreatitis due to pancreatic sphincter of Oddi dysfunction
T. Wehrmann (2000)
10.1056/NEJM199609263351301
Complications of endoscopic biliary sphincterotomy.
M. Freeman (1996)
10.1067/MGE.2003.29
Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial.
M. Moretó (2003)
10.1046/J.0007-1323.2001.01842.X
Prospective randomized double‐blind placebo‐controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography‐induced pancreatitis
S. Sudhindran (2001)
10.1016/S0016-5107(00)70377-4
Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
A. Andriulli (2000)
10.1055/S-2001-16520
A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis.
A. Budzyńska (2001)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar